May 5, 2017 6:53pm

 

Investors are lucky one day (Monday) and burned for six (including last Friday)

As I had stated, “Investors are worried about the constancy of share pricing alteration –there is a need to consider not just when to sell but why to buy!”

 

High volatility and modulating volume are the cause and causality of the caprices of the cell therapy sector.

 

Pre-open indications: 4 hits and 2 miss

 

The truth is harsh, but reality is what it is!

 

I answer one question, in which company should investors commit and keep their money

 

 

 

RMi’s daily and continual “reads” of the goings-on of the SCG&RT sector can improve investor’s and trader’s odds - just because a stock underperforms the market doesn’t mean you have to lose money.

 

 

Henry’omics:

From the pre-open’s investor’s newsletter “The rotation continues … and share pricing risks are increasing as Q1 financial results are announced.”

  • Reiterating,” With the sector flirting with new lows, some investors have reckoned the sector is self-destructing – which is a partial truth; however drug discovery as everyone knows, offers more risks than rewards.”

Trading ranges have been all over the map i.e. downward today and this week which tells us a few things – as I stated this am – yet another rotation!

 

I believe the issues surrounding the declines relate to Q1 financial results – spending is up with minimal results as compared to Q4/16.

 

 

Daily analytics:

U.S. equities closed luckily UP on Friday … with the DOW closing up +0.26% as the NASDAQ closed up +0.42% … after

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 10.7 …

·  Thursday traded near 10.48 following Wednesday ‘s near 10.7,  Tuesday trading near 9.90, Monday near 10.2 and last Friday near 10.9;

 

Welcome to another day of the sector’s roller coaster …

… The iShares Russell 2000 (IWM) indicated a positive +0.11% at the pre-open was and closed UP +0.64%;

… The iShares NASDAQ Biotechnology (IBB) did NOT indicate at the pre-open and closed DOWN -0.86%

 

 

The advance/decline line scenario of 43 SCGT & RT covered companies:   

·         The open was negative  with an A/DL of 12/27 and 4 flats;

·         The mid-day stayed negative with an A/DL of 9/30 and 4 flats;

·         The close was negative with an A/DL of 15/24 and 4 flats;

 

 

Friday’s count - decliners versus gainers: look at the differences in the spreads and advance/decline lines:

Friday’s decliners ranged from -0.41% <ONCE> to -12.83% <IMUC> in 24 equities;

·         Thursday’s decliners ranged from -0.05% <XON> to -14.22% <IMUC> in 22 equities;

·         Wednesday’s decliners ranged from -0.15% <BSTG> to -7.02% <RGNX> in 24 equities;

·         Tuesday’s decliners ranged from -0.04% <CLLS> to -7.19% <RGNX> in 29 equities;

·         Monday’s decliners ranged from -0.28% <NWBO> to -10.81% <AST> in 8 equities;

Versus

Friday’s gainers ranged from +0.37% <ONVO> to +8.09% <AXGN> in 15 equities;

·         Thursday’s gainers ranged from +0.34% <ONCE> to +6.82% <BLUE> in 14 equities;

·         Wednesday’s gainers ranged from +0.20% <CLLS> to +4.95% <BLFS> in 14 equities;

·         Tuesday’s gainers ranged from +0.28% <NWBO> to +5.11% <MDXG> in 13 equities;

·         Monday’s gainers ranged from +0.02% <MESO> to +12.12% <VTGN> in 33 equities;

 

 

Pre-open indications: 4 hit and 2 miss

  • AxoGen (AXGN) closed UP +$0.95 – miss, even with all that debt;
  • Biostage (BSTG) closed flat $0.00 – hit;
  • Fate Therapeutics (FATE) closed up +$0.05 – hit;
  • Juno Therapeutics JUNO) closed down -$1.97 – hit;
  • Osiris (OSIR) closed up +$0.07 – miss, even with legal “Sword of Damocles” hanging over its head;
  • Sangamo Biosciences (SGMO closed DOWN -$0.05 – hit;

 

Percentage gainers:

·         AxoGen (AXGN) +8.09% after Thursday’s -4.47%,

·         BioLife Solutions (BLFS) +3.90%,

·         Caladrius Biosciences (CLBS) +3.63%,

·         MiMedx (MDXG) +2.10%,

·         Verastem (VSTM) +1.98%,

 

Percentage losers:

·         ImmunoCellular (NYSEMKT: IMUC) -12.83% after Thursday’s -14.22%,

·         Opexa (OPXA) -9.38%,

·         Juno therapeutics (JUNO) -7.68%,

·         Fibrocell (FCSC) -4.99%,

·         Neuralstem (CUR) -4.45%,

 

Dollar gainers:

·         AxoGen (AXGN) +$0.95 after Thursday’s -$0.55,

·         MiMedx (MDXG) +$0.29,

·         Caladrius Biosciences (CLBS) +$0.18,

·         BioLife Solutions (BLFS) +$0.08,

·         Osiris (OSIR) +$0.07 after Thursday’s +$0.24 after Wednesday’s+$0.11 after Tuesday’s +$0.10

 

 

Dollar losers:

·         bluebird Bio (BLUE) -$2.90 after Thursday’s +$5.95 after Wednesday’s -$0.90 after Tuesday’s -$2.45 after Monday’s +$1.65,

·         Kite Pharma (KITE) -$2.00 after Thursday’s +$2.42,

·         Juno Therapeutics (JUNO) -$1.97 after Thursday’s +0.54 after Wednesday’s -$0.43 after Tuesday’s +0.21,

·         Cellectis SA (CLLS) -$1.04 after Thursday’s +$1.37,

·         Intrexon (XON) -$0.56,

 

Flats:

·         Adverum (ADVM),

·         International Stem Cell (ISCO),

·         Aduro Biotech (ADRO)

·         ReNeuron (RENE.L),

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.